US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma

Date: April 22, 2011
Pages: 35
Price:
US$ 2,999.00 US$ 500.00
License [?]:
Publisher: The Assessment Group
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U72A1010F9AEN
Leaflet:

Download PDF Leaflet

US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma
Two patient specific case scenarios on advanced non-Hodgkin’s lymphoma involving patients with a) relapsed large cell lymphoma and b) large cell lymphoma with compromised cardiac function that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal:
  • Decisions in treatment and tests through disease stages
  • Factors influencing their decisions
  • Barriers to optimal patient care
  • Confidence in treatment
Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on advanced non-Hodgkin’s lymphoma.

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance
EXECUTIVE SUMMARY

CHAPTER 1: INTRODUCTION

Table 1. Treatment Options in Non-Hodgkin’s Lymphoma

CHAPTER 2: RESPONDENT DEMOGRAPHICS

Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.6 Survey Respondents by State’s Non-Hodgkin’s Lymphoma Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

CHAPTER 3: PATIENT WITH RELAPSED LARGE CELL LYMPHOMA

Figure 3.1 Barriers to optimal care of large cell lymphoma
Figure 3.2 Confidence in treatment
Figure 3.3 First line treatment approach to patient with large cell lymphoma
Figure 3.4 Factors that influence treatment decision
Figure 3.5 Preferred R-CHOP regimen
Figure 3.6 Next step in management following R-CHOP
Figure 3.7 Treatment for progressing B-cell large cell lymphoma
Figure 3.8 Factors influencing treatment decision
Figure 3.9 Treatment following response then relapse from second-line therapy

CHAPTER 4: PATIENT WITH LARGE CELL LYMPHOMA WITH COMPROMISED CARDIAC FUNCTION

Figure 4.1 Confidence in treatment for large cell lymphoma with compromised cardiac function
Figure 4.2 Treatment approach for large cell lymphoma with compromised cardiac function
Figure 4.3 Factors influencing treatment of large cell lymphoma with compromised cardiac function
Figure 4.4 Treatment approach for large cell lymphoma with compromised cardiac function
Figure 4.5 Second-line treatment for large cell lymphoma with compromised cardiac function

CHAPTER 5: SUMMARY

Appendix A: Survey Instrument
Skip to top


Ask Your Question

US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: